688 related articles for article (PubMed ID: 24120656)
21. MSN anti-cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition.
He Q; Shi J
Adv Mater; 2014 Jan; 26(3):391-411. PubMed ID: 24142549
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in delivery of drug-nucleic acid combinations for cancer treatment.
Li J; Wang Y; Zhu Y; Oupický D
J Control Release; 2013 Dec; 172(2):589-600. PubMed ID: 23624358
[TBL] [Abstract][Full Text] [Related]
23. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
Retnakumari AP; Hanumanthu PL; Malarvizhi GL; Prabhu R; Sidharthan N; Thampi MV; Menon D; Mony U; Menon K; Keechilat P; Nair S; Koyakutty M
Mol Pharm; 2012 Nov; 9(11):3062-78. PubMed ID: 22971013
[TBL] [Abstract][Full Text] [Related]
24. Biological rationale for the design of polymeric anti-cancer nanomedicines.
Zhou Y; Kopeček J
J Drug Target; 2013 Jan; 21(1):1-26. PubMed ID: 23009337
[TBL] [Abstract][Full Text] [Related]
25. Research progress of novel inorganic nanometre materials carriers in nanomedicine for cancer diagnosis and treatment.
Xu J; Liao K; Jiang H; Zhou W
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S492-S502. PubMed ID: 30449177
[TBL] [Abstract][Full Text] [Related]
26. Optimization of the tumor microenvironment and nanomedicine properties simultaneously to improve tumor therapy.
Zhang B; Shi W; Jiang T; Wang L; Mei H; Lu H; Hu Y; Pang Z
Oncotarget; 2016 Sep; 7(38):62607-62618. PubMed ID: 27566585
[TBL] [Abstract][Full Text] [Related]
27. Recent progress in nanomedicine for enhanced cancer chemotherapy.
Wei G; Wang Y; Yang G; Wang Y; Ju R
Theranostics; 2021; 11(13):6370-6392. PubMed ID: 33995663
[TBL] [Abstract][Full Text] [Related]
28. Particle carriers for combating multidrug-resistant cancer.
Yan Y; Björnmalm M; Caruso F
ACS Nano; 2013 Nov; 7(11):9512-7. PubMed ID: 24215340
[TBL] [Abstract][Full Text] [Related]
29. Innovative nanochemotherapy for overcoming cancer multidrug resistance.
Tan H; Zhang M; Wang Y; Timashev P; Zhang Y; Zhang S; Liang XJ; Li F
Nanotechnology; 2021 Nov; 33(5):. PubMed ID: 34700307
[TBL] [Abstract][Full Text] [Related]
30. Nanomedicine based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: In vitro evaluation on 2D and 3D tumor models.
Sarisozen C; Dhokai S; Tsikudo EG; Luther E; Rachman IM; Torchilin VP
Eur J Pharm Biopharm; 2016 Nov; 108():54-67. PubMed ID: 27569031
[TBL] [Abstract][Full Text] [Related]
31. Overcoming cellular multidrug resistance using classical nanomedicine formulations.
Kunjachan S; Błauż A; Möckel D; Theek B; Kiessling F; Etrych T; Ulbrich K; van Bloois L; Storm G; Bartosz G; Rychlik B; Lammers T
Eur J Pharm Sci; 2012 Mar; 45(4):421-8. PubMed ID: 21907796
[TBL] [Abstract][Full Text] [Related]
32. Nanomedicine-mediated cancer stem cell therapy.
Shen S; Xia JX; Wang J
Biomaterials; 2016 Jan; 74():1-18. PubMed ID: 26433488
[TBL] [Abstract][Full Text] [Related]
33. Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics.
Marchal S; El Hor A; Millard M; Gillon V; Bezdetnaya L
Drugs; 2015 Sep; 75(14):1601-11. PubMed ID: 26323338
[TBL] [Abstract][Full Text] [Related]
34. Carbon nanotubes for delivery of small molecule drugs.
Wong BS; Yoong SL; Jagusiak A; Panczyk T; Ho HK; Ang WH; Pastorin G
Adv Drug Deliv Rev; 2013 Dec; 65(15):1964-2015. PubMed ID: 23954402
[TBL] [Abstract][Full Text] [Related]
35. Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance.
Pan J; Mendes LP; Yao M; Filipczak N; Garai S; Thakur GA; Sarisozen C; Torchilin VP
Eur J Pharm Biopharm; 2019 Mar; 136():18-28. PubMed ID: 30633973
[TBL] [Abstract][Full Text] [Related]
36. Nanomedicine: is it lost in translation?
Greish K; Mathur A; Bakhiet M; Taurin S
Ther Deliv; 2018 Mar; 9(4):269-285. PubMed ID: 29495928
[TBL] [Abstract][Full Text] [Related]
37. Tumor acidity activated triphenylphosphonium-based mitochondrial targeting nanocarriers for overcoming drug resistance of cancer therapy.
Yu H; Li JM; Deng K; Zhou W; Wang CX; Wang Q; Li KH; Zhao HY; Huang SW
Theranostics; 2019; 9(23):7033-7050. PubMed ID: 31660085
[TBL] [Abstract][Full Text] [Related]
38. Nanomedicine to overcome cancer multidrug resistance.
Yang X; Yi C; Luo N; Gong C
Curr Drug Metab; 2014; 15(6):632-49. PubMed ID: 25255871
[TBL] [Abstract][Full Text] [Related]
39. Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue.
Gote V; Nookala AR; Bolla PK; Pal D
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925129
[TBL] [Abstract][Full Text] [Related]
40. Nanomedicine to target multidrug resistant tumors.
Lepeltier E; Rijo P; Rizzolio F; Popovtzer R; Petrikaite V; Assaraf YG; Passirani C
Drug Resist Updat; 2020 Sep; 52():100704. PubMed ID: 32512316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
